Iovance Biotherapeutics pushes cell therapy platform into solid tumor marketProactive Investors • 06/01/26
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001GlobeNewsWire • 06/01/26
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?Zacks Investment Research • 05/28/26
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/07/26
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate UpdatesGlobeNewsWire • 05/07/26
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 04/30/26
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026GlobeNewsWire • 04/27/26
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/26/26
Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036The Motley Fool • 03/05/26
Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These YearsSeeking Alpha • 03/04/26
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline ProgressZacks Investment Research • 02/25/26
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)Seeking Alpha • 02/24/26
Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor FrenzyBenzinga • 02/24/26